29 September 2017 The RheumNow Week in Review Save

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report discusses regulatory actions by NICE and FDA, higher death rates in RA and psoriasis, increased risk of RA with Asthma, rising numbers for OA, RA, and STDs.

1. In RA, Smoking status recorded in 40%; cessation counseling in only 10% & was less likely when RA was controlled. https://buff.ly/2wWaHs2 
2. ~1/3 RA pts rank their Disease activity higher than their Rheumatologist; more likely seronegative RA, those in LDAS with FM, Depression, high pain scores. https://buff.ly/2xygaK0 
3. Higher MASEI (enthesitis) scores in PsA associated with more Joint damage, ankylosis, arthritis mutilans periostitis, axial Disease. https://buff.ly/2fU0k25 
4. Review shows antiphopholipid Abs associated with and increased risk of idiopathic pulm arterial HTN, left-side valvular heart dz https://t.co/79KG9Qfb6k
5. CDC: STDs new record high #s in 2016 - chlamydia (1.6mil), gonorrhea (470k) & syphilis (28k); more screening urged https://t.co/U6bsHAeWQa
6. In Australia from 2015 to 2030, OA numbers are expected to increase 41%; RA by 37%, with cost of care rising by 37% for both. https://t.co/BNc2P4CyU3
7. Mayo: 1996 to 2013, 58 cases of AAV in Olmstead Co - 23 GPA, 28 MPA & 7 EGPA. 60% MPO+, 30% PR3+: Prev 42.1/100,000 https://t.co/Q0n2Srmf7t
8. Olmstead Co. Mayo Clinic study shows asthma significantly associated with increased risk of RA (adj OR 1.74) https://t.co/lcqkjGu9BK 
9. Kevzara (sarilumab) has been recommended by UK NICE for use with MTX in adults with severe, active RA https://t.co/2fL8LDjLi3
10. FDA Panel Backs New Zoster Subunit Vaccine
11. Sirukumab Turned Down by FDA
12.  Psoriasis Increases Risk of Major Adverse Cardiovascular Events  
13. Increased Deaths in RA, Despite Decreasing Mortality Rates
14. No Cancer Risk With Biologic Use
15. The DownEaster Meeting – Westborough, MA  14 October 2017